Merkliste

LacriJet® is FCI latest and exclusive preloaded & self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.

Weitere Produktinformationen

LacriJet®

FCI EXCLUSIVE

LacriJet® is FCI latest and exclusive preloaded & self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.

It consists of a single use injector handpiece into which a silicone tube is preloaded inside a metallic probe. LacriJet® has been specifically designed to reduce operating time, either in the intubation phase as well as for the removal of the device.

Main characteristics:

  • Exclusive new injection system
  • Available in 7 lengths
  • 3 mm plug collarette
  • Sterile, Single use

LacriJet® is a Class IIb medical device manufactured by FCI S.A.S. - Notified Body: GMED CE n°0459.


Erhältlich bei:


Produkt direkt anfragen: